PMA supplement
P100034 S017: Novocure Ltd.'s Optune
FDA PMA supplement · 30-Day Notice · Novocure, GmbH
Key facts
| Original PMA | P100034 |
|---|---|
| Supplement number | S017 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | Novocure Ltd.'s Optune |
| Generic name | Stimulator, low electric field, tumor treatment |
| Applicant | Novocure, GmbH |
| Product code | NZK |
| Received date | Feb 13, 2017 |
| Decision date | Mar 15, 2017 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: